Natural history of functional decline in Alzheimer's disease: A systematic review

Journal of Alzheimer's Disease

Volumn 40, Issue 1, 2014, Pages 57-67

  Delva, Fleur ^a,b   Auriacombe, Sophie ^b   Letenneur, Luc ^a   Foubert Samier, Alexandra ^a,b   Bredin, Alain ^c   Clementy, Anne ^d   Latxague, Chrystelle ^b   Puymirat, Emmanuel ^e   Ballan, Guillaume ^f   Delabrousse Mayoux, Jean Phillipe ^c   Glénisson, Laurent ^b   Mazat, Lise ^g   Spampinato, Umberto ^a,b   Rainfray, Muriel ^a,b   Tison, François ^a,b   Dartigues, Jean François ^a,b  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b BORDEAUX UNIVERSITY HOSPITAL   (France)

^c Neurologist   (France)

^d Hôpital Suburbain du Bouscat   (France)

^e CLINIQUE SAINT AUGUSTIN   (France)

^f Service de Neurologie CH de Bayonne   (France)

^g CMP des Fontaines de Monjous   (France)

Author keywords

Activities of daily living; Alzheimer's disease; prognosis; review

Indexed keywords

AMYLOID PRECURSOR PROTEIN; CYANOCOBALAMIN; FOLIC ACID;

ALZHEIMER DISEASE; APATHY; ARTICLE; BATH; CAREGIVER; CHILD REARING; CLINICAL DEMENTIA RATING; CONTINENCE; DAILY LIFE ACTIVITY; DETERIORATION; DISEASE COURSE; FAMILY HISTORY; FINANCE; FIRST DEGREE RELATIVE; FOOD PROCESSING; FUNCTIONAL DISEASE; FUNCTIONAL STATUS; GENERAL CONDITION DETERIORATION; HETEROZYGOTE; HISTORY; HUMAN; LAUNDRY; LAWTON INSTRUMENTAL ACTIVITIES OF DAILY LIVING SCALE; LEISURE; METABOLISM; MINI MENTAL STATE EXAMINATION; PATIENT; PRIORITY JOURNAL; PROGNOSIS; SELF CARE; SHOPPING; SYSTEMATIC REVIEW; TRAFFIC AND TRANSPORT; WECHSLER INTELLIGENCE SCALE;

ACTIVITIES OF DAILY LIVING; ALZHEIMER'S DISEASE; PROGNOSIS; REVIEW;

ACTIVITIES OF DAILY LIVING; ALZHEIMER DISEASE; COGNITION DISORDERS; DATABASES, FACTUAL; DISEASE PROGRESSION; HUMANS; MEMORY DISORDERS; MENTAL STATUS SCHEDULE;

EID: 84901811446     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-131862     Document Type: Article

References (29)

1. Gaugler JE, Yu F, Krichbaum K, Wyman JF (2009) Predictors of nursing home admission for persons with dementia. Med Care 47, 191-198.
2. Mohamed S, Rosenheck R, Lyketsos CG, Schneider LS (2010) Caregiver burden in Alzheimer disease: Cross-sectional and longitudinal patient correlates. Am J Geriatr Psychiatry 18, 917-927.
3. Yaffe K, Fox P, Newcomer R, Sands L, Lindquist K, Dane K, Covinsky KE (2002) Patient and caregiver characteristics and nursing home placement in patients with dementia. JAMA 287, 2090-2097.
4. Gelb DJ (2000) Measurement of progression in Alzheimer's disease: A clinician's perspective. Stat Med 19, 1393-1400.
5. Desai AK, Grossberg GT, Sheth DN (2004) Activities of daily living in patients with dementia: Clinical relevance, methods of assessment and effects of treatment. CNS Drugs 18, 853-875.
6. Trinh NH, Hoblyn J, Mohanty S, Yaffe K (2003) Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: A meta-analysis. JAMA 289, 210-216.
7. Birks J (2006) Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev, CD005593.
8. Salmi LR (2002) Lecture critique et communication médicale scientifique. Comment lire, présenter, rédiger et publier une étude clinique ou épidémiologique, Elsevier, France.
9. Arrighi HM, Gelinas I, McLaughlin TP, Buchanan J, Gauthier S (2013) Longitudinal changes in functional disability in Alzheimer's disease patients. Int Psychogeriatr 25, 929-937.
10. Atchison TB, Massman PJ, Doody RS (2007) Baseline cognitive function predicts rate of decline in basic-care abilities of individuals with dementia of the Alzheimer's type. Arch Clin Neuropsychol 22, 99-107.
11. Cortes F, Gillette-Guyonnet S, Nourhashemi F, Andrieu S, Cantet C, Vellas B (2005) Recent data on the natural history of Alzheimer's disease: Results from the REAL.FR Study. J Nutr Health Aging 9, 86-93.
12. Cortes F, Gillette-Guyonnet S, Nourhashemi F, Christelle C, Vellas B (2006) Family historyof dementia does not influence the progression of Alzheimer's disease at two years: Results from the REAL.FR Study. Am J Alzheimers Dis Other Demen 21, 131-136.
13. Cortes F, Nourhashemi F, Guerin O, Cantet C, Gillette-Guyonnet S, Andrieu S, Ousset P-J, Vellas B, Real-Fr G (2008) Prognosis of Alzheimer's disease today: A two-year prospective study in 686 patients from the REAL-FR Study. Alzheimers Dement 4, 22-29.
14. Gillette-Guyonnet S, Andrieu S, Nourhashemi F, Gardette V, Coley N, Cantet C, Gauthier S, Ousset P-J, Vellas B, Grp RFS (2011) Long-term progression of Alzheimer's disease in patients under antidementia drugs. Alzheimers Dement 7, 579-592.
15. Hoyt BD, Massman PJ, Schatschneider C, Cooke N, Doody RS (2005) Individual growth curve analysis of APOE epsilon 4-associated cognitive decline in Alzheimer disease. Arch Neurol 62, 454-459.
16. Lechowski L, Benoit M, Chassagne P, Vedel I, Tortrat D, Teillet L, Vellas B (2009) Persistent apathy in Alzheimer's disease as an independent factor of rapid functional decline: The REAL longitudinal cohort study. Int J Geriatr Psychiatry 24, 341-346.
17. Lechowski L, De Stampa M, Tortrat D, Teillet L, Benoit M, Robert PH, Vellas B (2005) Predictive factors of rate of loss of autonomy in Alzheimer's disease patients. A prospective study of the REAL.FR Cohort. J Nutr Health Aging 9, 100-104.
18. Locascio JJ, Fukumoto H, Yap L, Bottiglieri T, Growdon JH, Hyman BT, Irizarry MC (2008) Plasma amyloid beta-protein and C-reactive protein in relation to the rate of progression of Alzheimer disease. Arch Neurol 65, 776-785.
19. Nourhashemi F, Gillette-Guyonnet S, Rolland Y, Cantet C, Hein C, Vellas B (2009) Alzheimer's disease progression in the oldest old compared to younger elderly patient: Data from the REAL.FR study. Int J Geriatr Psychiatry 24, 149-155.
20. Nourhashemi F, Ousset PJ, Gillette-Guyonnet S, Cantet C, Andrieu S, Vellas B (2008) A 2-year follow-up of 233 very mild (CDR 0.5) Alzheimer's disease patients (REAL.FR cohort). Int J Geriatr Psychiatry 23, 460-465.
21. Palmer K, Lupo F, Perri R, Salamone G, Fadda L, Caltagirone C, Musicco M, Cravello L (2011) Predicting disease progression in Alzheimer's disease: The role of neuropsychiatric syndromes on functional and cognitive decline. J Alzheimers Dis 24, 35-45.
22. Sanz CM, Hanaire H, Vellas BJ, Sinclair AJ, Andrieu S (2012) Diabetes mellitusasamodulatoroffunctional impairment and decline in Alzheimer's disease. The Real. FR cohort. Diabet Med 29, 541-548.
23. Soto ME, Andrieu S, Gillette-Guyonnet S, Cantet C, Nourhashemi F, Vellas B (2006) Risk factors for functional decline and institutionalisation among community-dwelling older adults with mild to severe Alzheimer's disease: One year of follow-up. Age Ageing 35, 308-310.
24. Suh GH, Ju YS, Yeon BK, Shah A (2004) Alongitudinal study of Alzheimer's disease: Rates of cognitive and functional decline. Int J Geriatr Psychiatry 19, 817-824.
25. Vellas B, Andrieu S, Cantet C, Dartigues JF, Gauthier S (2007) Long-term changes in ADAS-cog: What is clinically relevant for disease modifying trials in Alzheimer? J Nutr Health Aging 11, 338-341.
26. Derouesne C, Thibault S, Lozeron P, Baudouin-Madec V, Piquard A, Lacomblez L (2002) [Perturbations of activities of daily living in Alzheimer's disease. A study of 172 patients with the using a questionnaire completed by caregivers]. Rev Neurol (Paris) 158, 684-700.
27. Kleiman T, Zdanys K, Black B, Rightmer T, Grey M, Garman K, Macavoy M, Gelernter J, van Dyck C (2006) Apolipopro-tein E epsilon4 allele is unrelated to cognitive or functional declinein Alzheimer's disease: Retrospective and prospective analysis. Dement Geriatr Cogn Disord 22, 73-82.
28. Treiber KA, Carlson MC, Corcoran C, Norton MC, Breitner JC, Piercy KW, Deberard MS, Stein D, Foley B, Welsh-Bohmer KA, Frye A, Lyketsos CG, Tschanz JT (2011) Cognitive stimulation and cognitive and functional decline in Alzheimer's disease: The cache county dementia progression study. J Gerontol B Psychol Sci Soc Sci 66, 416-425.
29. Poewe W (2009) Clinical measures of progression in Parkinson's disease. Mov Disord 24(Suppl 2), S671-S676.